A Phase 1 Combined Single and Multiple Ascending Oral Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP7713 in Healthy Non-Japanese Adult and Elderly Subjects and Healthy Japanese Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2018
Price : $35 *
At a glance
- Drugs ASP 7713 (Primary)
- Indications Bladder dysfunction
- Focus Adverse reactions
- Sponsors Astellas Pharma BV
- 06 Mar 2018 Status changed from suspended to completed.
- 24 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Aug 2018.
- 24 Oct 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Aug 2018.